Chemotherapy for hepatitis B: New treatment options necessitate reappraisal of traditional endpoints

Gastroenterology

Volumn 123, Issue 6, 2002, Pages 2135-2140

  Shaw, Tim ^a   Bowden, Scott ^a   Locarnini, Stephen ^a  

^a VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 9 [2 (PHOSPHONOMETHOXY)ETHYL] 6 (4 METHOXYPHENYLTHIO)PURINEBIS(2,2,2 TRIFLUOROETHYL) ESTER; ADEFOVIR; ADEFOVIR DIPIVOXIL; ALAMIFOVIR; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; AMINOTRANSFERASE; ANTIVIRUS AGENT; CLEVUDINE; EMTRICITABINE; ENTECAVIR; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TELBIVUDINE; THYMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

CHEMOTHERAPY; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; GENE EXPRESSION; HEPATITIS B; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMMUNOMODULATION; INFECTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT PLANNING; VIRUS LOAD;

EID: 0036892312     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2002.37288     Document Type: Article

References (28)

1. Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis 2002;2:395-403.
2. Brechot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Brechot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: Clinically significant or purely "occult"? Hepatology 2001;34:194-203.
3. Conjeevaram HS, Lok AS. Occult hepatitis B virus infection: A hidden menace? Hepatology 2001;34:204-206.
4. Funk ML, Rosenberg DM, Lok AS. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat 2002;9:52-61.
5. Shaw T, Locarnini SA. Hepatic purine and pyrimidine metabolism: Implications for antiviral chemotherapy of viral hepatitis. Liver 1995;15:169-184.
6. Shaw T, Locarnini S. Combination chemotherapy for hepatitis B virus: The path forward? Drugs 2000;60:517-531.
7. Staschke KA, Colacino JM. Drug discovery and development of antiviral agents for the treatment of chronic hepatitis B virus infection. Prog Drug Res 2001;Spec No:111-183.
8. Zoulim F. A preliminary benefit-risk assessment of lamivudine for the treatment of chronic hepatitis B virus infection. Drug Saf 2002;25:497-510.
9. Gilson RJ, Chopra KB, Newell AM, Murray-Lyon IM, Nelson MR, Rice SJ, Tedder RS, Toole J, Jaffe HS, Weller IV. A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection. J Viral Hepat 1999;6:387-395.
10. Lewin SR, Ribeiro RM, Walters T, Lau GK, Bowden S, Locarnini S, Perelson AS. Analysis of hepatitis B viral load decline under potent therapy: Complex decay profiles observed. Hepatology 2001;34:1012-1020.
11. Tsiang M, Rooney JF, Toole JJ, Gibbs CS. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology 1999;29:1863-1869.
12. Wolters LM, Hansen BE, Niesters HG, Zeuzem S, Schalm SW, de Man RA. Viral dynamics in chronic hepatitis B patients during lamivudine therapy. Liver 2002;22:121-126.
13. Wolters LM, Hansen BE, Niesters HG, DeHertogh D, de Man RA. Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B. J Hepatol 2002;37:137-144.
14. Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, Gutfreund K, Lamy P, Murray A. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000;32:129-134.
15. Levine S, Hernandez D, Yamanaka G, Zhang S, Rose R, Weinheimer S, Colonno RJ. Efficacies of Entecavir against Lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother 2002;46:2525-2532.
16. Lai C-L, Rosmawati M, Lao J, Van Vlierberghe H, Anderson FH, Thomas N, DeHertogh D. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002;123:1831-1838.
17. de Man RA, Wolters LM, Nevens F, Chua D, Sherman M, Lai CL, Gadano A, Lee Y, Mazzotta F, Thomas N, DeHertogh D. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology 2001;34:578-582.
18. Colonno RJ, Genovesi EV, Medina I, Lamb L, Durham SK, Huang ML, Corey L, Littlejohn M, Locarnini S, Tennant BC, Rose B, Clark JM. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J Infect Dis 2001;184:1236-1245.
19. Marion PL, Salazar FH, Winters MA, Colonno RJ. Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication. Antimicrob Agents Chemother 2002;46:82-88.
20. Newbold JE, Xin H, Tencza M, Sherman G, Dean J, Bowden S, Locarnini S. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J Virol 1995;69:3350-3357.
21. Lewin S, Walters T, Locarnini S. Hepatitis B treatment: Rational combination chemotherapy based on viral kinetic and animal model studies. Antiviral Res 2002;55:381-396.
22. Whalley SA, Murray JM, Brown D, Webster GJ, Emery VC, Dusheiko GM, Perelson AS. Kinetics of acute hepatitis B virus infection in humans. J Exp Med 2001;193:847-854.
23. Gauthier J, Bourne EJ, Lutz MW, Crowther LM, Dienstag JL, Brown NA, Condreay LD. Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine. J Infect Dis 1999;180:1757-1762.
24. Ohkubo K, Kato Y, Ichikawa T, Kajiya Y, Takeda Y, Higashi S, Hamasaki K, Nakao K, Nakata K, Eguchi K. Viral load is a significant prognostic factor for hepatitis B virus-associated hepatocellular carcinoma. Cancer 2002;94:2663-2668.
25. Lau GK, Leung YH, Fong DY, Au WY, Kwong YL, Lie A, Hou JL, Wen YM, Nanj A, Liang R. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 2002;99:2324-2330.
26. Delaney WE 4th, Locarnini S, Shaw T. Resistance of hepatitis B virus to antiviral drugs: Current aspects and directions for future investigation. Antivir Chem Chemother 2001;12:1-35.
27. Colgrove R, Japour A. A combinatorial ledge: Reverse transcriptase fidelity, total body viral burden, and the implications of multiple-drug HIV therapy for the evolution of antiviral resistance. Antiviral Res 1999;41:45-56.
28. Werle B, Wursthorn K, Petersen J, Bowden S, Locarnini S, Lau G, Trepo C, James C, Brosgart C, Xiong S, Delaney IV W, Gibbs C, Zoulim F. Quantitative analyses of hepatic HBV cccDNA during the natural history of chronic hepatitis B and adefovir dipivoxil therapy: An International, Multicentre Study. Hepatology 2002;36(4,Pt2):296A.